Drug Trial Radar · NCT00264953
HD11 for Intermediate Stages
Last checked: Nov 20, 2026Latest source record: Aug 4, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,395
Actual
Start
May 1998
Primary completion
Jan 2003
Sponsor
- Lead sponsor
- University of CologneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 13, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to (1) compare the efficacy of the BEACOPP regimen with that of ABVD as a 4-cycle chemotherapy combined with an involved field irradiation and (2) to define the optimum radiation dose comparing of 30 to 20 Gy in the same context.
Conditions
- Hodgkin´s Lymphoma
Interventions
AdriamycinDrug
BleomycinDrug
VinblastineDrug
DTICDrug
EtoposideDrug
ProcarbazineDrug
PrednisoneDrug
VincristineDrug
radiation therapyRadiation
20 or 30Gy IF-RT
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.